MAY 28, 2020 8:30 AM PDT

Trial for Arthritis Drug with Remdesivir to Beat COVID-19

WRITTEN BY: Annie Lennon

Montefiore Health System and Albert Einstein College of Medicine in New York have teamed up to see how well remdesivir, a drug already approved for COVID-19 treatment, works with an anti-inflammatory drug known as baricitinib against the virus. 

Preliminary results from clinical trials with remdesivir have shown that the drug is able to reduce recovery times from COVID-19 from 15 days to 11 days. Of the 1,063 patients involved in that trial, 91 were from either Montefiore or Einstein hospitals. 

Expanding on these results, doctors and researchers between these hospitals are studying whether remdesivir in combination with baricitinib can yield even better results. Baricitinib is so far known for reducing inflammation linked to rheumatoid arthritis. The researchers' goal is to determine whether the drug, when taken with remdesivir, reduces or prevents cytokine storms (excessive inflammation), which can overwhelm a patient's lungs and other organs, eventually leading to death. 

To do so, they are conducting a placebo-controlled, double-blind, randomized trial for the drug combination. Patients selected for the trial should be hospitalized with a confirmed COVID-19 diagnosis and lung complications, including abnormal chest X-rays, pneumonia, and need of a mechanical ventilator to breathe. While all patients will receive remdesivir intravenously for up to 10 days, half of the patients will be given baricitinib by mouth, and the other half an identical placebo, for up to two weeks. 

"What concerns us is that in some people the immune response to coronavirus can be more deadly than the infection itself, and there is no known treatment for this yet," says Barry Zingman, one of the study's authors also involved in the original remdesivir study. 

"Including baricitinib in our trial may reduce COVID-19-related inflammation and combining baricitinib with remdesivir may yield an even more effective treatment option for people most severely affected by this illness." 


Sources: Science Daily, News Medical

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
NOV 18, 2021
Cannabis Sciences
Could Cannabis-Based Compounds Be the Next New Class of Antibiotics?
NOV 18, 2021
Could Cannabis-Based Compounds Be the Next New Class of Antibiotics?
According to the Centers for Disease Prevention and Control (CDC), antibiotic-resistant bacterial or fungal strains infe ...
DEC 02, 2021
Immunology
New mRNA Vaccine Stops Ticks, Prevents Lyme Disease
DEC 02, 2021
New mRNA Vaccine Stops Ticks, Prevents Lyme Disease
Yale University researchers have developed an mRNA vaccine against ticks that could help prevent Lyme disease. This is a ...
DEC 02, 2021
Microbiology
A 'Bispecific Antibody' to Fight Crimean-Congo Hemorrhagic Fever
DEC 02, 2021
A 'Bispecific Antibody' to Fight Crimean-Congo Hemorrhagic Fever
Crimean-Congo hemorrhagic fever (CCHF) is a deadly disease, which is fatal in about 30 percent of cases. It's caused ...
DEC 01, 2021
Drug Discovery & Development
Researchers Use Ultrasound to Remove Diseased Brain Cells
DEC 01, 2021
Researchers Use Ultrasound to Remove Diseased Brain Cells
Researchers have developed a noninvasive method to remove faulty brain circuits using ultrasound and microbubbles. The c ...
DEC 02, 2021
Cannabis Sciences
Can Cannabis Help Manage Autistic Spectrum Disorder?
DEC 02, 2021
Can Cannabis Help Manage Autistic Spectrum Disorder?
Autistic Spectrum Disorder (ASD) is a developmental disorder characterized by persistent deficits in social interaction, ...
DEC 15, 2021
Drug Discovery & Development
New study launches Viagra into the spotlight as the next drug to treat Alzheimer's disease
DEC 15, 2021
New study launches Viagra into the spotlight as the next drug to treat Alzheimer's disease
A recent study, published in the journal Nature Aging, reaffirmed the role of Sildenafil (brand name Viagra) in tre ...
Loading Comments...